Literature DB >> 26409282

Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children.

James A Seddon1, Lindsay McKenna2, Tejshri Shah3, Beate Kampmann4.   

Abstract

Tuberculosis in children accounts for a significant proportion of the overall burden of disease, and yet for many years research into pediatric treatment has been neglected. Recently, there have been major developments in our understanding of pediatric tuberculosis, and a large number of studies are under way or planned. New drugs and regimens are being evaluated, and older drugs are being repurposed. Shorter regimens with potentially fewer side effects are being assessed for the treatment and prevention of both drug-susceptible and drug-resistant tuberculosis. It may be possible to tailor treatment so that children with less severe disease are given shorter regimens, and weekly dosing is under investigation for preventive therapy and for the continuation phase of treatment. The interaction with human immunodeficiency virus and the management of tuberculosis meningitis are also likely to be better understood. Exciting times lie ahead for pediatric tuberculosis, but much work remains to be done.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  children; prevention; resistant; treatment; tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26409282     DOI: 10.1093/cid/civ582

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Outcomes across the tuberculosis care continuum among adolescents in Haiti.

Authors:  L K Reif; V Rivera; R Bertrand; V Rouzier; E Kutscher; K Walsh; B Charles; J W Pape; D W Fitzgerald; S P Koenig; M L McNairy
Journal:  Public Health Action       Date:  2018-09-21

2.  Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016.

Authors:  Arundhati Maitra; Tengku Karmila Kamil; Monisha Shaik; Cynthia Amaning Danquah; Alina Chrzastek; Sanjib Bhakta
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

3.  Association of HIV infection and antiretroviral therapy with the occurrence of an unfavorable TB treatment outcome in a rural district hospital in Eastern Cape, South Africa: A retrospective cohort study.

Authors:  Brittney J van de Water; Isabel Fulcher; Suretha Cilliers; Nadishani Meyer; Michael Wilson; Catherine Young; Ben Gaunt; Karl le Roux
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.752

4.  Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.

Authors:  Chishala Chabala; Anna Turkova; Anneke C Hesseling; Kevin M Zimba; Marieke van der Zalm; Monica Kapasa; Megan Palmer; Maxwell Chirehwa; Lubbe Wiesner; Eric Wobudeya; Aarti Kinikar; Vidya Mave; Syed Hissar; Louise Choo; Kristen LeBeau; Veronica Mulenga; Robb Aarnoutse; Diana Gibb; Helen McIlleron
Journal:  Clin Infect Dis       Date:  2022-05-30       Impact factor: 20.999

5.  BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome.

Authors:  Synne Jenum; Rasmus Bakken; S Dhanasekaran; Aparna Mukherjee; Rakesh Lodha; Sarman Singh; Varinder Singh; Marielle C Haks; Tom H M Ottenhoff; S K Kabra; T Mark Doherty; Christian Ritz; Harleen M S Grewal
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.